Oral orforglipron meets cardiovascular safety bar against insulin glargine in ACHIEVE-4
MACE occurred in 4.2% on orforglipron versus 5.0% on insulin glargine over a median two years, with gastrointestinal events far more common.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 03:00 ETSource: MedPage Today
The wire
- 01In adults with type 2 diabetes and overweight or obesity at cardiovascular risk, orforglipron met noninferiority for major adverse cardiovascular events against insulin glargine (HR 0.84, 95% CI 0.59-1.20), reported at EASD and published in The Lancet.
- 02The non-peptide oral GLP-1 agonist, already FDA approved for obesity, also showed sustained glycemic and weight improvements over 104 weeks, a 24.2% median drop in urinary albumin-to-creatinine ratio at week 52, and slower eGFR decline.
- 03ACHIEVE-4 was not powered for cardiovascular superiority; ATTAIN-Outcomes, testing orforglipron against placebo in established disease, is scheduled to complete in 2031. GI adverse events hit 62.1% versus 14.2% and drove discontinuations.
From the source
Read at medpagetoday.comNew Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says
— Orforglipron met expectations in ACHIEVE-4, with cardiovascular benefit yet to be proven
